What Researchers Did
Researchers reviewed existing evidence on the systematic clinical use of hyperbaric oxygen therapy (HBOT) for unestablished indications, particularly chronic brain injury, by examining multiple randomized, blinded, sham-controlled trials.
What They Found
The review found that multiple randomized, blinded, sham-controlled trials for hyperbaric oxygen therapy (HBOT) in conditions like cerebral palsy and mild traumatic brain injury showed no benefit compared to sham control. However, both HBOT and sham groups often improved, indicating a significant placebo or participation effect influenced outcomes in these studies.
What This Means for Canadian Patients
Canadian patients considering hyperbaric oxygen therapy (HBOT) for conditions like chronic brain injury should be aware that current evidence from rigorous trials does not support its benefit for these unestablished indications. It is important to discuss all treatment options with healthcare providers and prioritize therapies with proven efficacy to avoid treatments of doubtful benefit.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
As a review, this study's findings are dependent on the quality and completeness of the existing trials it analyzed.